Four batches and five rounds of nationally sourced varieties are compared. How long will it take to wait for the centralized procurement of biological medicines and Chinese patent medicines?

Image source: Dr.

Table 1 Overview of centralized procurement data

Image source: Dr.

Table 2 Comparison of the decline in the recent three batches of centralized procurement

Figure 3 The lowest unit price ranking of centralized procurement varieties

Figure 4 The lowest unit price ranking of the fourth batch of centralized procurement varieties

Figure 5 Distribution of dosage forms of centralized procurement varieties

The collection of traditional Chinese medicine and biological analogues is approaching

The centralized procurement that has been carried out so far is all chemical drugs, and no biological drugs and traditional Chinese medicines have been included.
On the eve of the Spring Festival, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Mass Procurement of Drugs".
The document clearly stated that: Over-evaluated varieties, proprietary Chinese medicines and biosimilar drugs will be included in the collection of medicines
.
And at the regular policy briefing on January 28, Chen Jinfu, deputy director of the National Medical Insurance Administration, also made it clear that the inclusion of biosimilar drugs and proprietary Chinese medicines in centralized procurement is an institutional requirement, and there is no doubt that they should be included in centralized procurement
.

On February 18, CDE issued the "Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars", which means that the consistency evaluation of biosimilars is about to start, and the inclusion of biosimilars in centralized drug procurement is a foregone conclusion.
The distance from the collection is getting closer and closer
.

It can be seen that the national centralized drug procurement will fully cover all types of drugs, the system will be more complete, and the comfort zone of Chinese patent medicine and biopharmaceutical manufacturers will no longer be durable; foreign investment in high-priced biopharmaceuticals may also face the challenge of substantial price cuts
.

The General Office of the State Council issued the "Opinions on Promoting the Normalization and Institutionalization of Centralized and Volume Purchase of Drugs", which clarified the normalization and institutionalization of centralized and volumetric procurement of drugs.
This major decision document also indicates the next few years.
Concentrated procurement with volume will become the mainstream trend of drug procurement.
While ensuring quality, tiered development, full collection and encouragement of local volume procurement, etc.
, will bring more impact to the industry
.